drugset
drugset / Trial / NCT02852551

Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of PAT-1251 in Healthy Adult Subjects

NCT02852551 ↗

Phase 1 Completed 78 enrolled PharmAkea, Inc.
RandomizedParallel-groupTriple-blindBasic science

Summary

A single-center, randomized, placebo-controlled study consisting of both a single ascending dose (SAD) and a multiple ascending dose (MAD) portion to evaluate the safety, tolerability, pharmacokinetics and effect of food using PAT-1251 orally administered to healthy subjects

Timeline

Start
2016-07
Primary completion
2016-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject PAT-1251 Unknown 150 mg Oral
Subject PAT-1251 Unknown 2000 mg Oral
Subject PAT-1251 Unknown 4000 mg Oral

Indications

No indication recorded.